Journal ArticleDOI
Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma
Supritha G. Swamy,H. K. Vivek,Priya Babu Shubha,Chung Yeng Looi,Muthu K. Shanmugam,Frank Arfuso,Arunasalam Dharmarajan,Gautam Sethi,Gautam Sethi,Nanjunda Swamy Shivananju,Anupam Bishayee +10 more
TLDR
The diverse signal transduction pathways responsible for initiation as well as progression of HCC and also the potential anticancer effects of selected targeted therapies that can be employed for HCC therapy are summarized.Abstract:
Hepatocellular carcinoma (HCC) is one of the most common forms of liver cancer diagnosed worldwide. HCC occurs due to chronic liver disease and is often diagnosed at advanced stages. Chemotherapeutic agents such as doxorubicin are currently used as first-line agents for HCC therapy, but these are non-selective cytotoxic molecules with significant side effects. Sorafenib, a multi-targeted tyrosine kinase inhibitor, is the only approved targeted drug for HCC patients. However, due to adverse side effects and limited efficacy, there is a need for the identification of novel pharmacological drugs beyond sorafenib. Several agents that target and inhibit various signaling pathways involved in HCC are currently being assessed for HCC treatment. In the present review article, we summarize the diverse signal transduction pathways responsible for initiation as well as progression of HCC and also the potential anticancer effects of selected targeted therapies that can be employed for HCC therapy.read more
Citations
More filters
Journal ArticleDOI
Sorafenib: A Review in Hepatocellular Carcinoma.
TL;DR: Subsequent results from real-world studies such as GIDEON also support the use of sorafenib in HCC, including in carefully selected CP class B patients, although the median OS achieved in these patients appears relatively short.
Journal ArticleDOI
An Update on Pharmacological Potential of Boswellic Acids against Chronic Diseases.
Nand Kishor Roy,Dey Parama,Kishore Banik,Devivasha Bordoloi,Amrita Khwairakpam Devi,Krishan Kumar Thakur,Ganesan Padmavathi,Mehdi Shakibaei,Lu Fan,Gautam Sethi,Ajaikumar B. Kunnumakkara +10 more
TL;DR: The present review is an attempt to demonstrate the diverse pharmacological uses of BA, along with its underlying molecular mechanism of action against different ailments, and the roadblocks associated with the pharmacokinetics and bioavailability of this promising compound.
Journal ArticleDOI
Honokiol for cancer therapeutics: A traditional medicine that can modulate multiple oncogenic targets.
Kishore Banik,Abhishek Manoj Ranaware,Vishwas Deshpande,Savita Pravin Nalawade,Ganesan Padmavathi,Devivasha Bordoloi,Bethsebie Lalduhsaki Sailo,Muthu K. Shanmugam,Lu Fan,Frank Arfuso,Gautam Sethi,Ajaikumar B. Kunnumakkara +11 more
TL;DR: The current review describes in detail the various reports supporting these anti-cancer studies documented with this promising agent honokiol.
Journal ArticleDOI
Piceatannol: A natural stilbene for the prevention and treatment of cancer.
Kishore Banik,Abhishek Manoj Ranaware,Choudhary Harsha,Thakur Nitesh,Sosmitha Girisa,Vishwas Deshpande,Lu Fan,Savita Pravin Nalawade,Gautam Sethi,Ajaikumar B. Kunnumakkara +9 more
TL;DR: This review supports Piceatannol as a potential anticancer and chemopreventive agent and suggests that it can be effectively employed as a capable anti-cancer drug.
Journal ArticleDOI
Potential of Zerumbone as an Anti-Cancer Agent.
Sosmitha Girisa,Bano Shabnam,Javadi Monisha,Lu Fan,Clarissa Esmeralda Halim,Frank Arfuso,Kwang Seok Ahn,Gautam Sethi,Ajaikumar B. Kunnumakkara +8 more
TL;DR: Zerumbone has shown its anti-cancer effects by causing significant suppression of proliferation, survival, angiogenesis, invasion, and metastasis through the molecular modulation of different pathways such as NF-κB, Akt, and IL-6/JAK2/STAT3 (interleukin- 6/janus kinase-2/signal transducer and activator of transcription 3) and their downstream target proteins.
References
More filters
Journal ArticleDOI
Global cancer statistics
TL;DR: A substantial proportion of the worldwide burden of cancer could be prevented through the application of existing cancer control knowledge and by implementing programs for tobacco control, vaccination, and early detection and treatment, as well as public health campaigns promoting physical activity and a healthier dietary intake.
Journal ArticleDOI
The hallmarks of cancer.
TL;DR: This work has been supported by the Department of the Army and the National Institutes of Health, and the author acknowledges the support and encouragement of the National Cancer Institute.
Journal ArticleDOI
Global cancer statistics, 2012
Lindsey A. Torre,Freddie Bray,Rebecca L. Siegel,Jacques Ferlay,Joannie Lortet-Tieulent,Ahmedin Jemal +5 more
TL;DR: A substantial portion of cancer cases and deaths could be prevented by broadly applying effective prevention measures, such as tobacco control, vaccination, and the use of early detection tests.
Journal ArticleDOI
Management of hepatocellular carcinoma.
Jordi Bruix,Morris Sherman +1 more
TL;DR: The prevention of Cirrhosis can prevent the development of HCC and progression from chronic HCV infection to advanced fibrosis or cirrhosis may be prevented in 40% of patients who are sustained responders to new antiviral strategies, such as pegylated interferon and ribavirin.
Journal ArticleDOI
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Ann-Lii Cheng,Yoon-Koo Kang,Zhendong Chen,Chao Jung Tsao,Shukui Qin,Jun Suk Kim,Rongcheng Luo,Jifeng Feng,Sheng-Long Ye,Tsai Sheng Yang,Jianming Xu,Yan Sun,Houjie Liang,Jiwei Liu,Jiejun Wang,Won Young Tak,Hongming Pan,Karin Burock,Jessie Zou,D. Voliotis,Zhongzhen Guan +20 more
TL;DR: Sorafenib is effective for the treatment of advanced hepatocellular carcinoma in patients from the Asia-Pacific region, and is well tolerated.